1. DOP81 Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn's Disease in the SERENE studies. (21st January 2022) Authors: Verstockt, B; Al Mahi, N; Pivorunas, V; Smaoui, N; Guay, H; Kennedy, N A; Hanauer, S B; Ferrante, M; Panés, J; Vermeire, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗